Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORMANDY: Non-operative Management of Rectal Cancer
NCT04696757Phase 2Completed
- Sponsor
- Kangbuk Samsung Hospital
- Start
- Feb 2018
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in rectal cancer, sponsored by Kangbuk Samsung Hospital. Started Feb 2018; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04696757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696757.